Metavention in January closed a $65 million Series C round, with funding from New Enterprise Associates, Sanderling Ventures and others. The money is going toward optimizing Metavention’s transcatheter-based metabolic neuromodulation therapy for people with Type II diabetes. The company at the time said it was preparing for a Phase II trial in the U.S.
The goal is to “provide improved control of elevated glucose, in a single minimally invasive procedure,” according to CEO Todd Berg.
–Chris Newmarker, Managing Editor